Misaki Ise-Kinoshita

Mitaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Journal: American journal of clinical dermatology

Published: July 28, 2026

Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience.

Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience.

Journal: Immunological medicine

Published: March 27, 2026

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Journal: American journal of clinical dermatology

Published: February 20, 2026

Trichotemnomania: A Case Report With Insights Into the Techniques Enabling Effective Diagnosis.

Trichotemnomania: A Case Report With Insights Into the Techniques Enabling Effective Diagnosis.

Journal: The Journal of dermatology

Published: July 24, 2025

Japanese Dermatological Association's Clinical Practice Guidelines for Alopecia Areata 2024: A Complete English Translated Version.

Japanese Dermatological Association's Clinical Practice Guidelines for Alopecia Areata 2024: A Complete English Translated Version.

Journal: The Journal of dermatology

Published: June 26, 2025

Hyperpigmented Drug Eruption Caused by Sanshishi (Gardenia Fruit): A Rare and Potentially Overlooked Skin Manifestation.

Hyperpigmented Drug Eruption Caused by Sanshishi (Gardenia Fruit): A Rare and Potentially Overlooked Skin Manifestation.

Journal: The Journal of dermatology

Published: May 22, 2025

Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata.

Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata.

Journal: The Journal of investigative dermatology

Published: January 29, 2025

Validity and Advantages of Three-Dimensional High-Frequency Ultrasound in Dermatological Evaluation.

Validity and Advantages of Three-Dimensional High-Frequency Ultrasound in Dermatological Evaluation.

Journal: Diagnostics (Basel, Switzerland)

Published: December 10, 2024

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.

Journal: The Journal of dermatology

Published: September 30, 2024

Long-term outcomes of intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata: A single-center retrospective analysis of 106 cases and usefulness evaluation of a scoring system originally designed for half-year efficacy prediction for extended periods.

Long-term outcomes of intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata: A single-center retrospective analysis of 106 cases and usefulness evaluation of a scoring system originally designed for half-year efficacy prediction for extended periods.

Journal: The Journal of dermatology

Published: July 15, 2024

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 05, 2024

Updated epidemiology of alopecia areata in Germany: the data tell a lot but hide a lot.

Updated epidemiology of alopecia areata in Germany: the data tell a lot but hide a lot.

Journal: The British journal of dermatology

Published: October 29, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026